Literature DB >> 24020743

Epidemiology and treatment of mucormycosis.

Russell E Lewis1, Dimitrios P Kontoyiannis.   

Abstract

Mucormycosis is an uncommon but aggressive opportunistic fungal infection that afflicts patients with severe underlying immunosuppression, uncontrolled hyperglycemia and/or ketoacidosis, patients with iron overload resulting from frequent blood transfusions or blood disorders and occasionally healthy patients who are inoculated with fungal spores through traumatic injuries. The clinical presentation of mucormycosis is initially indistinguishable from other common infections, and if not diagnosed early and aggressively treated, it is almost always fatal. In this article we summarize recent changes in the epidemiology of mucormycosis, discuss diagnostic and clinical clues suggestive of the infection and provide a general strategy for managing the infection in the absence of data from well-controlled, prospective clinical trials.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24020743     DOI: 10.2217/fmb.13.78

Source DB:  PubMed          Journal:  Future Microbiol        ISSN: 1746-0913            Impact factor:   3.165


  36 in total

1.  Novel therapeutic use of Versajet for intestinal mucormycosis.

Authors:  William Calvert; Dhanya Mullassery; Rajeev Shukla; Graham Lamont
Journal:  BMJ Case Rep       Date:  2014-03-03

2.  How I transplant a patient with a history of invasive fungal disease.

Authors:  Pedro Puerta-Alcalde; Richard Champlin; Dimitrios P Kontoyiannis
Journal:  Blood       Date:  2020-08-26       Impact factor: 22.113

3.  Effect of Preexposure to Triazoles on Susceptibility and Virulence of Rhizopus oryzae.

Authors:  Anne-Pauline Bellanger; Nathaniel D Albert; Russell E Lewis; Thomas J Walsh; Dimitrios P Kontoyiannis
Journal:  Antimicrob Agents Chemother       Date:  2015-09-21       Impact factor: 5.191

4.  Statin Concentrations Below the Minimum Inhibitory Concentration Attenuate the Virulence of Rhizopus oryzae.

Authors:  Anne-Pauline Bellanger; Alexander M Tatara; Fazal Shirazi; Teclegiorgis Gebremariam; Nathaniel D Albert; Russell E Lewis; Ashraf S Ibrahim; Dimitrios P Kontoyiannis
Journal:  J Infect Dis       Date:  2016-03-16       Impact factor: 5.226

5.  The Celecoxib Derivative AR-12 Has Broad-Spectrum Antifungal Activity In Vitro and Improves the Activity of Fluconazole in a Murine Model of Cryptococcosis.

Authors:  Kristy Koselny; Julianne Green; Louis DiDone; Justin P Halterman; Annette W Fothergill; Nathan P Wiederhold; Thomas F Patterson; Melanie T Cushion; Chad Rappelye; Melanie Wellington; Damian J Krysan
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

6.  How I perform hematopoietic stem cell transplantation on patients with a history of invasive fungal disease.

Authors:  Pedro Puerta-Alcalde; Richard E Champlin; Dimitrios P Kontoyiannis
Journal:  Blood       Date:  2020-12-10       Impact factor: 22.113

7.  Successful Treatment of Primary Cutaneous Mucormycosis Complicating Anti-TNF Therapy with a Combination of Surgical Debridement and Oral Posaconazole.

Authors:  Jose F Camargo; Danny Yakoub; Jeong Hee Cho-Vega
Journal:  Mycopathologia       Date:  2015-06-26       Impact factor: 2.574

Review 8.  Primary Cutaneous Mucormycosis Caused by Rhizopus oryzae: A Case Report and Review of Literature.

Authors:  Erika Rodríguez-Lobato; Lourdes Ramírez-Hobak; Jorge E Aquino-Matus; Juan P Ramírez-Hinojosa; Víctor H Lozano-Fernández; Juan Xicohtencatl-Cortes; Rigoberto Hernández-Castro; Roberto Arenas
Journal:  Mycopathologia       Date:  2016-11-03       Impact factor: 2.574

9.  Effects of Photodynamic Inactivation on the Growth and Antifungal Susceptibility of Rhizopus oryzae.

Authors:  Zhaoyang Liu; Jing Tang; Yi Sun; Lujuan Gao
Journal:  Mycopathologia       Date:  2019-01-28       Impact factor: 2.574

10.  Aggressive Combined Medical and Surgical Management of Mucormycosis Results in Disease Eradication in 2 Pediatric Patients.

Authors:  Haley F M Augustine; Colin White; James Bain
Journal:  Plast Surg (Oakv)       Date:  2017-06-28       Impact factor: 0.947

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.